Evidence map›Paper›PMID 35470452›Full record

ArticleBritish journal of clinical pharmacology2022

Histamine-2 (H

Emma Foreman, Calum Polwart, Andrew Walker, Pinkie Chambers

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
  4. Histamine-2 (HBritish journal of clinical pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Emma ForemanThe Royal Marsden NHS Foundation Trust, London, UK.ORCID 0000-0002-4348-9040
Calum PolwartSouth Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.ORCID 0000-0002-4774-6366
Andrew WalkerThe Mid Yorkshire Hospitals NHS Trust, Wakefield, UK.ORCID 0000-0002-7836-4686
Pinkie ChambersDepartment of Practice and Policy, UCL School of Pharmacy & University College London Hospitals NHS Foundation Trust, London, UK.ORCID 0000-0002-6669-9411
Mid Yorkshire Hospitals NHS Trust · GBRoyal Marsden NHS Foundation Trust · GBSouth Tees Hospitals NHS Foundation Trust · GBUniversity College London Hospitals NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine-2 (H

methodThis prospective, multi-centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H

resultsA total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H

conclusionsResults presented within the study are consistent with other recently published evidence to suggest that H

Indexed as

Antineoplastic Agents, PhytogenicDrug HypersensitivityCohort StudiesDexamethasoneHistamineHistamine H1 AntagonistsHistamine H2 AntagonistsHumansPaclitaxelPremedicationProspective StudiesAntineoplastic Agents, PhytogenicDexamethasoneHistamineHistamine H1 AntagonistsHistamine H2 AntagonistsPaclitaxelchemotherapyH2 antagonistshypersensitivitypaclitaxel

Identifiers

PMID35470452
PMCPMC9545865
OpenAlexW4224861365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.